Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 383 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar JMorril2 (59.86) Submitted: 3/3/2015 3:19:14 PM : Outperform Start Price: $102.90 GILD Score: -0.14

Low P/E, high upside

Recs

0
Member Avatar AdamGalas (< 20) Submitted: 3/3/2015 12:48:18 AM : Outperform Start Price: $103.84 GILD Score: -0.85

A Grand Adventure Dividend Holding:

http://boards.fool.com/the-grand-adventure-121197.aspx

Recs

0
Member Avatar Reddragyn (69.24) Submitted: 3/2/2015 6:48:21 AM : Outperform Start Price: $104.30 GILD Score: -1.61

MagInvPlus

Recs

0
Member Avatar WhatsNext1 (< 20) Submitted: 2/16/2015 7:33:47 PM : Outperform Start Price: $102.06 GILD Score: -0.11

Gileads Harvoni's drug will maintain a 10 to 20% growth rate worldwide for 10 years+ based on the millions that have hep c and the 5% more each year that will discover they have it.Their pipeline will continue to grow more dollars, and Gilead will probably make another acquisition in the next 2 years.

Recs

0
Member Avatar gunnersdad (57.75) Submitted: 2/15/2015 11:04:07 PM : Outperform Start Price: $102.06 GILD Score: -0.11

Biospharmaceuticals are only just beginning to be applied, and the companies focus on treating viral illness affecting large populations will allow it to capture new treatment areas previously inaccessable.

Recs

0
Member Avatar GhostSeraph (< 20) Submitted: 2/14/2015 9:50:32 PM : Outperform Start Price: $102.06 GILD Score: -0.11

Gilead is currently best of class in the market with its Hepatitis C cure, continues to dominate HIV, and boasts a promising pipeline.

Recs

0
Member Avatar Sargent18 (24.36) Submitted: 2/14/2015 11:53:12 AM : Outperform Start Price: $103.02 GILD Score: -0.41

Great company.

Recs

0
Member Avatar jakebvt (50.90) Submitted: 2/11/2015 5:49:41 PM : Outperform Start Price: $100.62 GILD Score: +0.60

Over 100% Q/Q sales growth, over 300% EPS Q/Q growth, most analysts peg it at $120, good ROA, ROI, ROE, margins, etc. P/E pretty low at 13. Huge pipeline with lots of potential to either sell patents or market drugs. Director recently bought $100,000 worth of shares.

Recs

1
Member Avatar Gibbs721 (37.78) Submitted: 2/6/2015 7:16:15 AM : Outperform Start Price: $99.73 GILD Score: +0.86

Still a very strong company, but has recently dropped in price due to expectations of slower growth.

Recs

1
Member Avatar emrichjj1 (< 20) Submitted: 1/31/2015 10:01:08 AM : Outperform Start Price: $104.61 GILD Score: -8.23

hep c cash flow support acquisitions

Recs

0
Member Avatar jbond009 (46.79) Submitted: 1/23/2015 3:49:17 PM : Outperform Start Price: $104.97 GILD Score: -6.21

Stock has been very volatile given news around sovaldi and Express scripts. This is very big news for this stock given how much sale of this medicine is part of the total revenue for this company. Technically stock should go up higher from this level for 1 year. However, need to listen in to the recent conference call to further understand what are the under currents for this pricing war and what kind of discounting is going on.

Recs

1
Member Avatar optioncoach (97.89) Submitted: 1/23/2015 2:53:44 PM : Outperform Start Price: $105.43 GILD Score: -5.34

Biotech continues to lead the markets. GILD had a pretty tough hit with the pricing issue, but I feel that they have based out and will continue to prove to be a leader in their area of expertise. It is a new buy at this point.

Recs

1
Member Avatar Jordrok (98.91) Submitted: 1/19/2015 7:54:34 PM : Outperform Start Price: $101.14 GILD Score: -2.68

Mechanical investing.

Recs

0
Member Avatar mike2r (68.53) Submitted: 1/19/2015 6:44:41 PM : Outperform Start Price: $101.14 GILD Score: -2.68

It has a very strong pipeline in areas that are very profitable. First, HIV. They have the only drug (Truvada) approved as a preventative measure and in their pipeline are working toward a one pill a day treatment for HIV.

In hepatitis, they have probably the strongest portfolio of drugs. Harvoni was recently released which cures Hepitits C in 8-12 weeks with one pill a day and no significant side effects.

For hepititis B they have two of the most effective treatments.

They also are developing a strong pipeline for cancer treatment.

Theses are all areas of significant opportunity and Despite the competitive environment, i think they are well positioned.

Recs

0
Member Avatar Kidkerner (62.93) Submitted: 1/15/2015 9:02:11 AM : Outperform Start Price: $99.30 GILD Score: -1.19

Hep C, industry leader.

Recs

0
Member Avatar Popolago (< 20) Submitted: 1/8/2015 8:36:11 PM : Outperform Start Price: $103.52 GILD Score: -2.99

GREATLY UNDERVALUED

Recs

0
Member Avatar moneymn (68.81) Submitted: 1/7/2015 6:34:04 PM : Outperform Start Price: $100.80 GILD Score: -1.51

Superior pipeline and current drugs on the market

Recs

1
Member Avatar TMFHelical (99.10) Submitted: 1/7/2015 4:24:33 PM : Outperform Start Price: $96.67 GILD Score: +5.20

Good long term holding. The company has been creating value for some time. Added on an opportunistic drop created after Abbvie's competition in the Hep-C space got approval. Could dent Gilead in the short term, but not hardly in the long haul.

Recs

1
Member Avatar Kenji94 (71.34) Submitted: 1/2/2015 9:04:41 AM : Outperform Start Price: $95.14 GILD Score: +5.74

At least 20% below intrinsec value.

Recs

0
Member Avatar Kimer62 (45.40) Submitted: 12/27/2014 10:23:29 AM : Outperform Start Price: $93.71 GILD Score: +5.65

Strong company purchase on pull back from express scripts fiasco.

Featured Broker Partners


Advertisement